Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach. J Med Virol. 2020;1--14. 10.1002/jmv.25736 31502247

Manojit Bhattacharya and Ashish R. Sharma contributed equally to the study.

**Disclosures**: None.

1. INTRODUCTION {#jmv25736-sec-0010}
===============

At the end of 2019, a novel coronavirus (SARS‐COV‐2) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei province of China.[^1^](#jmv25736-bib-0001){ref-type="ref"} It has a positive‐sense single‐stranded RNA as their genetic component and shares genome similarity with SARS‐CoV and bat coronavirus,[^2^](#jmv25736-bib-0002){ref-type="ref"}, [^3^](#jmv25736-bib-0003){ref-type="ref"} 79.5% and 96% respectively. Phylogenetically, it belongs to the family Coronaviridae, order Nidovirales and is a β‐coronavirus of 2B group.[^4^](#jmv25736-bib-0004){ref-type="ref"}

Regarding epidemiology, human‐to‐human transmission of the virus through the sneezes, cough, and respiratory droplets has been confirmed, yet the zoonotic nature has not been confirmed.[^5^](#jmv25736-bib-0005){ref-type="ref"}, [^6^](#jmv25736-bib-0006){ref-type="ref"}, [^7^](#jmv25736-bib-0007){ref-type="ref"} Epidemiologic investigation in Wuhan, China identified an initial association with a seafood market where most patients had worked or visited.[^4^](#jmv25736-bib-0004){ref-type="ref"} However, as the outbreak progressed, several confirmed cases were reported sporadically all over the world, showing the pandemic nature of the disease named as COVID‐19. At last, on 30 January 2020, the World Health Organization (WHO) declared this outbreak a public health emergency of international concern.[^8^](#jmv25736-bib-0008){ref-type="ref"} According to the situation report 35 (reported by 24 February 2020) of WHO, in China, 77 262 confirmed cases were reported, of which 2595 cases were with deaths. Moreover, outside of China, 2069 confirmed cases were reported in 29 other countries (<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200224-sitrep-35-covid-19.pdf?sfvrsn=1ac4218d_2>).

Therefore, as the situation was getting worse and worse, the need for designing a suitable peptide vaccine component against the SARS‐COV‐2 was growing. Our work was to find suitable epitopes, which can generate enough immune response against the SARS‐COV‐2 infection. Using immunoinformatics, we could recognize and characterize potential B and T‐cell epitopes for the generation of the epitopic vaccine against SARS‐COV‐2.[^9^](#jmv25736-bib-0009){ref-type="ref"} Specifically, the spike glycoprotein of SARS‐COV‐2 is considered as the target because it forms a characteristic crown of the virus and protrudes from the viral envelope.[^10^](#jmv25736-bib-0010){ref-type="ref"} So, the protein sequence of spike glycoprotein was explored thoroughly using multiple immunoinformatic‐based servers and software, to identify various epitopes for an effective vaccine.

2. MATERIALS AND METHODS {#jmv25736-sec-0020}
========================

2.1. Collection of targeted protein sequence {#jmv25736-sec-0030}
--------------------------------------------

The amino acid sequence of the targeted protein on SARS‐COV‐2 was collected from the National Centre for Biotechnological Information (NCBI) database.[^11^](#jmv25736-bib-0011){ref-type="ref"} The protein sequence is very crucial for identifying the potential epitopes of the targeted protein.

2.2. Identification of B‐cell epitopes {#jmv25736-sec-0040}
--------------------------------------

In this subsection, we used the Immune Epitope Database (IEDB) to identify linear B‐cell epitopes using the incorporated BepiPred 2.0 prediction module.[^12^](#jmv25736-bib-0012){ref-type="ref"}, [^13^](#jmv25736-bib-0013){ref-type="ref"} We provided the FASTA sequence of the targeted protein as an input considering all default parameters.

2.3. Identification of T‐cell epitopes and antigenicity analysis {#jmv25736-sec-0050}
----------------------------------------------------------------

T‐cell epitopes having the binding affinity towards MHC‐I and MHC‐II alleles were selected to boost up both cytotoxic T‐cell and helper T‐cell mediated immune response. We adopted two servers which are ProPred‐I and ProPred server to the selection of MHC‐I and MHC‐II binding epitopes respectively within preidentified B‐cell epitopic region.[^14^](#jmv25736-bib-0014){ref-type="ref"}, [^15^](#jmv25736-bib-0015){ref-type="ref"} The selected epitopes were submitted to the VaxiJen v.2.0 server applying a virus as a target field with the given threshold value of 0.4 for analyzing the antigenic propensity.[^16^](#jmv25736-bib-0016){ref-type="ref"}

2.4. Vaccine construction, modeling, and validation {#jmv25736-sec-0060}
---------------------------------------------------

With the help of a specific peptide linker, we fused the antigenic epitopes to construct an effectual vaccine component. Later, the vaccine component was modeled in the SPARKS‐X server.[^17^](#jmv25736-bib-0017){ref-type="ref"} An adjuvant was also added with the vaccine component to accelerate the adaptive immune responses. The vaccine model passed through two different servers ProSA‐web and PROCHECK---in a subsequent manner for evaluating the structural accuracy of the model.[^18^](#jmv25736-bib-0018){ref-type="ref"}, [^19^](#jmv25736-bib-0019){ref-type="ref"}

2.5. Molecular docking analysis {#jmv25736-sec-0070}
-------------------------------

Molecular docking is the most promising part of the modern drug‐discovery method. Here, in this study, we adopted PatchDock (Beta 1.3 Version) docking server to receptor‐ligand docking.[^20^](#jmv25736-bib-0020){ref-type="ref"} PatchDock server analyzes the molecular docking between the vaccine component and the toll‐like receptor (TLR)‐5. The generated Protein Data Bank (PDB) file of the protein‐peptide docking complex was visualized in PyMOL software v.2.3.[^21^](#jmv25736-bib-0021){ref-type="ref"}

3. RESULT {#jmv25736-sec-0080}
=========

3.1. Collection of targeted protein sequence {#jmv25736-sec-0090}
--------------------------------------------

Spike glycoprotein of SARS‐COV‐2, retrieved from the NCBI has the GenBank accession ID: QHR63290.1. This spike glycoprotein has 1282‐long amino acid sequences and this sequence was downloaded in a FASTA format to carry out the further process.

3.2. Identification of B‐cell epitopes {#jmv25736-sec-0100}
--------------------------------------

We obtained a total of 34 sequential linear B‐cell epitopes of varying lengths from the IEDB server within spike glycoprotein of SARS‐COV‐2. Those B‐cell epitopes were placed into Table [1](#jmv25736-tbl-0001){ref-type="table"} based on their positional value, sequence, and length. In Figure [1](#jmv25736-fig-0001){ref-type="fig"} the yellow‐colored peaks represent the epitopic region, while the green‐colored slopes, represent the nonepitopic region.

###### 

List of linear B‐cell epitopes along with their sequence, position, and length

  Serial no.   Start   End    Sequence                                                         Length
  ------------ ------- ------ ---------------------------------------------------------------- --------
  1            22      46     SQCVNLTTRTQLPPAYTNSFTRGVY                                        25
  2            68      90     FSNVTWFHAIHVSGTNGTKRFDN                                          23
  3            106     107    KS                                                               2
  4            147     163    DPFLGVYYHKNNKSWME                                                17
  5            186     198    MDLEGKQGNFKNL                                                    13
  6            215     230    KHTPINLVRDLPQGFS                                                 16
  7            259     269    TPGDSSSGWTA                                                      11
  8            302     305    LDPL                                                             4
  9            313     331    KSFTVEKGIYQTSNFRVQP                                              19
  10           338     372    FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA                              35
  11           378     402    YNSASFSTFKCYGVSPTKLNDLCFT                                        25
  12           413     435    GDEVRQIAPGQTGKIADYNYKLP                                          23
  13           449     510    NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN   62
  14           525     545    ELLHAPATVCGPKKSTNLVKN                                            21
  15           564     571    SNKKFLPF                                                         8
  16           589     592    QTLE                                                             4
  17           611     615    TNTSN                                                            5
  18           625     641    NCTEVPVAIHADQLTPT                                                17
  19           643     653    RVYSTGSNVFQ                                                      11
  20           665     675    VNNSYECDIPI                                                      11
  21           681     699    ASYQTQTNSPRRARSVASQ                                              19
  22           704     719    YTMSLGAENSVAYSNN                                                 16
  23           757     757    E                                                                1
  24           782     788    EQDKNTQ                                                          7
  25           795     809    KQIYKTPPIKDFGGF                                                  15
  26           816     823    PDPSKPSK                                                         8
  27           837     851    LADAGFIKQYGDCLG                                                  15
  28           997     1001   EAEVQ                                                            5
  29           1044    1052   GQSKRVDFC                                                        9
  30           1116    1127   RNFYEPQIITTD                                                     12
  31           1142    1181   VNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGI                         40
  32           1212    1215   LGKY                                                             4
  33           1261    1276   SCCKFDEDDSEPVLKG                                                 16
  34           1278    1278   K                                                                1
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![Graphical representation of linear B‐cell epitopes within the spike glycoprotein of SARS‐COV‐2](JMV-9999-na-g001){#jmv25736-fig-0001}

3.3. Identification of T‐cell epitopes and antigenicity analysis {#jmv25736-sec-0110}
----------------------------------------------------------------

We identified 29 MHC‐I epitopes and 8 MHC‐II epitopes, which fall within the preidentified B‐cell epitopic region. Among them, 13 MHC‐I epitopes and 3 MHC‐II epitopes had the antigenic propensity, according to the VaxiJen v.2.0 server analysis. The MHC‐I and MHC‐II epitopes are listed in Tables [2](#jmv25736-tbl-0002){ref-type="table"} and [3](#jmv25736-tbl-0003){ref-type="table"} with encountering MHC alleles and antigenic scores.

###### 

List of epitopes with encountering MHC‐I alleles, positional value, and VaxiJen antigenic score

  Serial no.       Epitopic sequence   MHC‐I alleles   Position    Antigenicity
  ---------------- ------------------- --------------- ----------- --------------------------------
  1                SQCVNLTTR           HLA‐A\*3101     22‐30       1.5476 (Probable Antigen).
  HLA‐A\*3302                                                      
  HLA‐A68.1                                                        
  HLA‐A20 Cattle                                                   
  HLA‐B\*2705                                                      
  MHC‐Db revised                                                   
  2                YTNSFTRGV           HLA‐A2          37‐45       −0.6177 (Probable Nonantigen).
  HLA‐A\*0201                                                      
  HLA‐A2.1                                                         
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B\*5801                                                      
  HLA‐B61                                                          
  3                GVYYHKNNK           HLA‐A\*1101     151‐159     0.8264 (Probable Antigen).
  HLA‐A3                                                           
  HLA‐A\*3101                                                      
  HLA‐A68.1                                                        
  HLA‐B\*2705                                                      
  4                GKQGNFKNL           HLA‐A2          190‐198     1.0607 (Probable Antigen).
  HLA‐A20 Cattle                                                   
  HLA‐B\*3902                                                      
  HLA‐Cw\*0301                                                     
  MHC‐Db                                                           
  MHC‐Db revised                                                   
  MHC‐Dd                                                           
  MHC‐Kb                                                           
  5                TPINLVRDL           HLA‐A24         217‐225     0.3862 (Probable Nonantigen).
  HLA‐B14                                                          
  HLA‐B\*3501                                                      
  HLA‐B\*3801                                                      
  HLA‐B\*3901                                                      
  HLA‐B\*3902                                                      
  HLA‐B40                                                          
  HLA‐B\*4403                                                      
  HLA‐B\*5101                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5103                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B60                                                          
  HLA‐B7                                                           
  HLA‐B\*0702                                                      
  HLA‐B8                                                           
  HLA‐Cw\*0301                                                     
  HLA‐Cw\*0401                                                     
  HLA‐Cw\*0602                                                     
  HLA‐Cw\*0702                                                     
  MHC‐Kd                                                           
  MHC‐Ld                                                           
  6                GIYQTSNFR           HLA‐A\*1101     320‐328     0.5380 (Probable Antigen).
  HLA‐A3                                                           
  HLA‐A\*3101                                                      
  HLA‐A\*3302                                                      
  HLA‐A68.1                                                        
  HLA‐A20 Cattle                                                   
  HLA‐B\*2705                                                      
  7                NLCPFGEVF           HLA‐A1          343‐351     0.1999 (Probable Nonantigen).
  HLA‐A3                                                           
  HLA‐A2.1                                                         
  HLA‐B\*2702                                                      
  HLA‐B\*5201                                                      
  HLA‐B\*5801                                                      
  HLA‐B62                                                          
  MHC‐Ld                                                           
  8                FASVYAWNR           HLA‐A\*3101     356‐364     0.0713 (Probable Nonantigen).
  HLA‐A\*3102                                                      
  HLA‐A68.1                                                        
  HLA‐A20 Cattle                                                   
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  9                ASFSTFKCY           HLA‐A1          381‐389     0.2795 (Probable Nonantigen).
  HLA‐B\*2702                                                      
  HLA‐B\*3501                                                      
  HLA‐B\*4403                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B\*5801                                                      
  HLA‐Cw\*0702                                                     
  MHC‐Ld                                                           
  10               VSPTKLNDL           HLA‐A24         391‐399     1.4610 (Probable Antigen).
  HLA‐A2.1                                                         
  HLA‐B\*3501                                                      
  HLA‐B\*3902                                                      
  HLA‐B\*51                                                        
  HLA‐B\*5801                                                      
  HLA‐B60                                                          
  HLA‐B7                                                           
  HLA‐B8                                                           
  HLA‐Cw\*0401                                                     
  HLA‐Cw\*0602                                                     
  MHC‐Dd                                                           
  MHC‐Kb                                                           
  MHC‐Ld                                                           
  11               KIADYNYKL           HLA‐A2          426‐434     1.6639 (Probable Antigen).
  HLA‐A\*0201                                                      
  HLA‐A\*0205                                                      
  HLA‐A24                                                          
  HLA‐A3                                                           
  HLA‐A\*3101                                                      
  HLA‐A2.1                                                         
  HLA‐B\*2705                                                      
  HLA‐B\*3501                                                      
  HLA‐B\*3801                                                      
  HLA‐B\*3902                                                      
  HLA‐B7                                                           
  HLA‐Cw\*0401                                                     
  12               KVGGNYNYL           HLA‐A\*0201     453‐461     0.5994 (Probable Antigen).
  HLA‐A\*0205                                                      
  HLA‐A24                                                          
  HLA‐A68.1                                                        
  HLA‐B\*2705                                                      
  HLA‐B\*3501                                                      
  HLA‐B\*3801                                                      
  HLA‐B\*3902                                                      
  HLA‐B7                                                           
  HLA‐B\*0702                                                      
  HLA‐Cw\*0301                                                     
  MHC‐Db                                                           
  MHC‐Db revised                                                   
  MHC‐Kb                                                           
  13               RLFRKSNLK           HLA‐A2          463‐471     −0.2829 (Probable Nonantigen).
  HLA‐A\*1101                                                      
  HLA‐A3                                                           
  HLA‐A\*3101                                                      
  HLA‐A68.1                                                        
  HLA‐A20 Cattle                                                   
  HLA‐B\*2705                                                      
  14               FERDISTEI           HLA‐B\*3701     473‐481     −0.7442 (Probable Nonantigen).
  HLA‐B40                                                          
  HLA‐B\*4403                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B60                                                          
  HLA‐B61                                                          
  MHC‐Kk                                                           
  15               EGFNCYFPL           HLA‐A2          493‐501     0.5453 (Probable Antigen).
  HLA‐B14                                                          
  HLA‐B\*3902                                                      
  HLA‐B40                                                          
  HLA‐B\*5101                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5103                                                      
  HLA‐B\*5401                                                      
  HLA‐B60                                                          
  HLA‐B7                                                           
  HLA‐Cw\*0301                                                     
  MHC‐Dd                                                           
  MHC‐Kb                                                           
  16               ELLHAPATV           HLA‐A2          525‐533     0.2109 (Probable Nonantigen).
  HLA‐A\*0201                                                      
  HLA‐A2.1                                                         
  HLA‐B\*5103                                                      
  HLA‐B62                                                          
  17               GPKKSTNLV           HLA‐B\*3501     535‐543     0.6828 (Probable Antigen).
  HLA‐B\*5101                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5103                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B61                                                          
  HLA‐B7                                                           
  HLA‐B\*0702                                                      
  HLA‐B8                                                           
  HLA‐Cw\*0401                                                     
  MHC‐Ld                                                           
  18               TEVPVAIHA           HLA‐B\*3701     627‐635     0.2687 (Probable Nonantigen).
  HLA‐B40                                                          
  HLA‐B\*4403                                                      
  HLA‐B60                                                          
  HLA‐B61                                                          
  MHC‐Kk                                                           
  19               RVYSTGSNV           HLA‐A2          643‐651     0.2636 (Probable Nonantigen).
  HLA‐A\*0201                                                      
  HLA‐A\*0205                                                      
  HLA‐A2.1                                                         
  HLA‐B\*2702                                                      
  HLA‐B\*2705                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5103                                                      
  HLA‐B\*5201                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*0702                                                      
  20               NSYECDIPI           HLA‐B\*2702     667‐675     0.2216 (Probable Nonantigen).
  HLA‐B\*3501                                                      
  HLA‐B\*5101                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5103                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*5801                                                      
  MHC‐Db revised                                                   
  MHC‐Kk                                                           
  21               SPRRARSVA           HLA‐B\*3501     689‐697     0.7729 (Probable Antigen).
  HLA‐B\*5101                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B7                                                           
  HLA‐B\*0702                                                      
  HLA‐B8                                                           
  MHC‐Ld                                                           
  22               LGAENSVAY           HLA‐B\*3501     707‐715     0.4173 (Probable Antigen).
  HLA‐B\*4403                                                      
  HLA‐B\*51                                                        
  HLA‐B62                                                          
  HLA‐Cw\*0702                                                     
  MHC‐Dd                                                           
  23               KQIYKTPPI           HLA‐A2          795‐803     0.2705 (Probable Nonantigen).
  HLA‐A\*0201                                                      
  HLA‐A\*0205                                                      
  HLA‐B\*2702                                                      
  HLA‐B\*2705                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5201                                                      
  HLA‐B62                                                          
  HLA‐B\*0702                                                      
  MHC‐Dd                                                           
  MHC‐Kd                                                           
  24               FIKQYGDCL           HLA‐A2.1        842‐850     −0.4436 (Probable Nonantigen).
  HLA‐B\*3501                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  HLA‐B7                                                           
  HLA‐B8                                                           
  25               RNFYEPQII           HLA‐B\*2702     1116‐1124   0.3282 (Probable Nonantigen).
  HLA‐B\*2705                                                      
  HLA‐B\*5102                                                      
  HLA‐B\*5201                                                      
  HLA‐B\*5401                                                      
  26               VNNTVYDPL           HLA‐A24         1142‐1150   0.2397 (Probable Nonantigen).
  HLA‐B\*3701                                                      
  HLA‐B\*3902                                                      
  HLA‐B\*5301                                                      
  HLA‐B\*51                                                        
  HLA‐B60                                                          
  HLA‐B7                                                           
  HLA‐Cw\*0301                                                     
  MHC‐Kb                                                           
  27               ELDSFKEEL           HLA‐A2          1153‐1161   −0.6805 (Probable Nonantigen).
  HLA‐A3                                                           
  HLA‐A2.1                                                         
  HLA‐B\*3801                                                      
  HLA‐B\*3902                                                      
  HLA‐Cw\*0401                                                     
  HLA‐Cw\*0602                                                     
  28               FKNHTSPDV           HLA‐A2          1165‐1173   0.4846 (Probable Antigen).
  HLA‐A20 Cattle                                                   
  HLA‐A2.1                                                         
  HLA‐B\*5301                                                      
  HLA‐B\*5401                                                      
  HLA‐B\*51                                                        
  29               DEDDSEPVL           HLA‐B\*3701     1266‐1274   0.5104 (Probable Antigen).
  HLA‐B40                                                          
  HLA‐B\*4403                                                      
  HLA‐B60                                                          
  HLA‐B61                                                          
  MHC‐Kk                                                           
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###### 

List showing the epitopes with encountering MHC‐II alleles, positional value and VaxiJen antigenic score

  Serial no.   Sequence    Alleles     Position    VaxiJen score
  ------------ ----------- ----------- ----------- --------------------------------
  1            IHVSGTNGT   DRB1_0306   77‐85       0.8621 (Probable Antigen).
  DRB1_0307                                        
  DRB1_0308                                        
  DRB1_0311                                        
  DRB1_0401                                        
  DRB1_0404                                        
  DRB1_0410                                        
  DRB1_0421                                        
  DRB1_0423                                        
  DRB1_0426                                        
  2            VYYHKNNKS   DRB1_0306   152‐160     0.4510 (Probable Antigen).
  DRB1_0307                                        
  DRB1_0308                                        
  DRB1_0311                                        
  DRB1_0401                                        
  DRB1_0402                                        
  DRB1_0404                                        
  DRB1_0405                                        
  DRB1_0408                                        
  DRB1_0410                                        
  DRB1_0421                                        
  DRB1_0423                                        
  DRB1_0426                                        
  DRB1_1102                                        
  DRB1_1114                                        
  DRB1_1120                                        
  DRB1_1121                                        
  DRB1_1322                                        
  DRB1_1323                                        
  DRB1_1327                                        
  DRB1_1328                                        
  DRB1_1501                                        
  DRB1_1506                                        
  3            LVRDLPQGF   DRB1_0301   221‐229     0.1234 (Probable Nonantigen).
  DRB1_0305                                        
  DRB1_0306                                        
  DRB1_0307                                        
  DRB1_0308                                        
  DRB1_0309                                        
  DRB1_0311                                        
  DRB1_0421                                        
  DRB1_0426                                        
  DRB1_1107                                        
  4            VFNATRFAS   DRB1_0301   350‐358     0.1739 (Probable Nonantigen).
  DRB1_0305                                        
  DRB1_0309                                        
  DRB1_0802                                        
  DRB1_0804                                        
  DRB1_0813                                        
  DRB1_1101                                        
  DRB1_1102                                        
  DRB1_1104                                        
  DRB1_1106                                        
  DRB1_1107                                        
  DRB1_1114                                        
  DRB1_1120                                        
  DRB1_1121                                        
  DRB1_1301                                        
  DRB1_1302                                        
  DRB1_1304                                        
  DRB1_1307                                        
  DRB1_1311                                        
  DRB1_1322                                        
  DRB1_1323                                        
  DRB1_1327                                        
  DRB1_1328                                        
  DRB1_1501                                        
  DRB1_1506                                        
  5            YRLFRKSNL   DRB1_0101   462‐470     0.0522 (Probable Nonantigen).
  DRB1_0305                                        
  DRB1_0309                                        
  DRB1_0405                                        
  DRB1_0408                                        
  DRB1_0701                                        
  DRB1_0703                                        
  DRB1_0801                                        
  DRB1_0802                                        
  DRB1_0804                                        
  DRB1_0806                                        
  DRB1_0813                                        
  DRB1_0817                                        
  DRB1_1101                                        
  DRB1_1102                                        
  DRB1_1114                                        
  DRB1_1120                                        
  DRB1_1121                                        
  DRB1_1128                                        
  DRB1_1301                                        
  DRB1_1302                                        
  DRB1_1304                                        
  DRB1_1305                                        
  DRB1_1307                                        
  DRB1_1321                                        
  DRB1_1322                                        
  DRB1_1323                                        
  DRB1_1327                                        
  DRB1_1328                                        
  DRB1_1501                                        
  DRB1_1502                                        
  DRB1_1506                                        
  6            FERDISTEI   DRB1_0305   473‐481     −0.7442 (Probable Nonantigen).
  DRB1_0401                                        
  DRB1_0426                                        
  DRB1_0309                                        
  DRB1_0421                                        
  DRB1_0701                                        
  DRB1_0703                                        
  7            YQTQTNSPR   DRB1_0421   683‐691     −0.1787 (Probable Nonantigen).
  DRB1_0401                                        
  DRB1_0405                                        
  DRB1_0408                                        
  DRB1_0426                                        
  8            FKNHTSPDV   DRB1_0101   1166‐1174   0.4846 (Probable Antigen).
  DRB1_0309                                        
  DRB1_0401                                        
  DRB1_0405                                        
  DRB1_0421                                        
  DRB1_0426                                        
  DRB1_0701                                        
  DRB1_0703                                        
  DRB1_1114                                        
  DRB1_1120                                        
  DRB1_1302                                        
  DRB1_1323                                        
  DRB1_1502                                        
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3.4. Vaccine construction, modeling, and validation {#jmv25736-sec-0120}
---------------------------------------------------

In this study, we linked the 13 MHC‐I and 3 MHC‐II antigenic epitopes with (EAAAK)~3~ linker peptide to construct a vaccine component. This linker peptide was easily fused with the virus coat protein and increased stability as well as folding of the vaccine component.[^22^](#jmv25736-bib-0022){ref-type="ref"} The predicted structure of the vaccine component is shown in Figure [2](#jmv25736-fig-0002){ref-type="fig"}. It has 90.0%, 7.1%, 1.6%, and 1.3% residues in most favored, additionally allowed, generously allowed and disallowed regions respectively within PROCHECK as the validation server to generate Ramachandran plot. Using the ProSA server, the "*Z*" score was −3.82 and most of the residues had negative energy value as shown in Figure [3](#jmv25736-fig-0003){ref-type="fig"}. Results from both servers indicate the model is in a good quality.[^23^](#jmv25736-bib-0023){ref-type="ref"}, [^24^](#jmv25736-bib-0024){ref-type="ref"}

![Tertiary structural model of construct vaccine component](JMV-9999-na-g002){#jmv25736-fig-0002}

![Different molecular characterization of vaccine model. (a) All atoms at Ramachandran plot, (b) "*Z*" score plot of vaccine model in ProSA server, and (c) all residue energy plot](JMV-9999-na-g003){#jmv25736-fig-0003}

3.5. Molecular docking analysis {#jmv25736-sec-0130}
-------------------------------

The PatchDock server provided 20 docking complexes, and among them, we selected only the docking complex with the highest negative atomic contact energy (ACE) value for analysis. The ACE value of the docking complex was −259.62, which indicates spontaneous reactivity between the vaccine component and TLR‐5.[^25^](#jmv25736-bib-0025){ref-type="ref"} As proper protein‐protein docking regulates the cellular functions, the docking between the vaccine component and TLR‐5 will activate immune cascades for destroying the viral antigens.[^26^](#jmv25736-bib-0026){ref-type="ref"} The selected docking complex is shown in Figures [4](#jmv25736-fig-0004){ref-type="fig"} and [5](#jmv25736-fig-0005){ref-type="fig"}, along with molecular surface interaction as well as some bonding interactions.

![Docking complex exhibiting the surface interaction between vaccine component (cyan color) and toll‐like receptor‐5 (green color)](JMV-9999-na-g004){#jmv25736-fig-0004}

![Docking complex exhibiting the bonding interaction between vaccine component and toll‐like receptor‐5](JMV-9999-na-g005){#jmv25736-fig-0005}

4. DISCUSSION {#jmv25736-sec-0140}
=============

The SARS‐COV‐2, the causative pathogen for respiratory distress syndrome, led more than 10 000 people to infection all over the world, even several to death. After first identified in Wuhan, Hubei province of China, the COVID‐19 disease spread unchecked which finally became a global threat. Scientists from all over the world are struggling to find a solution to this evil outbreak.

In our present study, we attempted to find out various B‐cell and T‐cell epitopes against SARS‐COV‐2, using the immunoinformatics, as quick identification of B‐cell and T‐cell epitopes is crucial for designing of vaccine component against this disease. The spike glycoprotein was analyzed for B‐cell epitope identification in the IEDB server, and 34 linear B‐cell epitopes were identified as a result. Subsequently, the sequence was also analyzed in ProPred‐I and ProPred servers for the identification of the T‐cell epitope that can combine with MHC‐I and MHC‐II molecules. Fortunately, we found 29 epitopes against MHC‐I and 8 epitopes against MHC‐II that can be possibly used for vaccine. Unfortunately, antigenic characterization in VaxiJen v.2.0 discarded 16 MHC‐I epitopes out of 29 and 5 out of 8 MHC‐II epitopes as these seemed to be nonantigenic in nature. Nevertheless, we converted the antigenic epitopes into a single vaccine component, using (EAAAK)~3~ peptide linker.

Later, the vaccine component was modeled in the SPARK‐X server and validated in PROCHECK and ProSA. A total of 90% of nonglycine and nonproline residues presented within the most favored region, while the "*Z*" score of the model was −3.82. These results from both servers indicate the model is in good quality. Molecular docking between vaccine component and TLR‐5 showed significant ACE value, which indicates spontaneous reactivity within the receptor‐ligand complex.

All the observations of our present work depict the effectiveness of selected epitopes within the spike glycoprotein of SARS‐COV‐2. These epitopes can be used to make an immunogenic multi‐epitopic peptide vaccine against SARS‐COV‐2.

5. CONCLUSION {#jmv25736-sec-0150}
=============

Present immunoinformatic analysis pointed out 13 MHC‐I and 3 MHC‐II epitopes within the spike glycoprotein of SARS‐COV‐2. These epitopes are the ideal candidate to formulate a multi‐epitopic peptide vaccine, not only because of being selected from the linear B‐cell epitopic region but also because of their antigenic property was confirmed. Moreover, the molecular docking of vaccine components with the TLR‐5 proves the significance and effectiveness of these epitopes as an ideal vaccine candidate against SARS‐COV‐2. However, these immunoinformatic analyses require several in vitro and in vivo validations before formulating the vaccine to resist COVID‐19.
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